Corbus Pharmaceuticals Holding (NASDAQ:CRBP) — Stock Price
Corbus Pharmaceuticals Holding (NASDAQ:CRBP) is currently trading at $6.63 USD, down 4.19% today. Over the past 52 weeks, shares have ranged between $6.63 and $19.36. This page tracks Corbus Pharmaceuticals Holding's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see Corbus Pharmaceuticals Holding (CRBP) cash conversion ratio.
Corbus Pharmaceuticals Holding (CRBP) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Corbus Pharmaceuticals Holding's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Corbus Pharmaceuticals Holding Income Statement — Revenue, Profit & Earnings by Year
Corbus Pharmaceuticals Holding's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $881.71K |
| Cost of Revenue | $233.00K | $600.00K | $31.17 Million | $1.49 Million | $1.64 Million |
| Gross Profit | $-233.00K | $-600.00K | $-31.17 Million | $-1.49 Million | $-757.53K |
| Research & Development | $70.09 Million | $32.22 Million | $31.17 Million | $16.14 Million | $36.45 Million |
| SG&A | $15.21 Million | $16.50 Million | $13.91 Million | $18.70 Million | $20.43 Million |
| Total Operating Expenses | $85.31 Million | $48.12 Million | $45.08 Million | $33.35 Million | $55.23 Million |
| Operating Income | $-85.31 Million | $-48.72 Million | $-45.08 Million | $-34.84 Million | $-55.99 Million |
| EBITDA | $-78.30 Million | $-37.74 Million | $-40.10 Million | $-38.73 Million | $-42.17 Million |
| EBIT | $-78.54 Million | $-38.34 Million | $-40.75 Million | $-40.21 Million | $-43.81 Million |
| Interest Expense | $0.00 | $1.87 Million | $2.92 Million | $2.13 Million | $1.83 Million |
| Income Before Tax | $-78.54 Million | $-40.21 Million | $-44.60 Million | $-42.35 Million | $-45.64 Million |
| Income Tax Expense | — | — | — | $13.49 Million | $-87.84K |
| Net Income | $-78.54 Million | $-40.21 Million | $-44.60 Million | $-55.83 Million | $-45.55 Million |
Corbus Pharmaceuticals Holding Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Corbus Pharmaceuticals Holding's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $168.19 Million | $155.88 Million | $28.27 Million | $66.31 Million | $107.73 Million |
| Total Current Assets | $166.95 Million | $152.98 Million | $23.55 Million | $60.18 Million | $100.20 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $134.78 Million | $131.86 Million | $7.18 Million | $42.19 Million | $72.64 Million |
| Net Receivables | $1.50 Million | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | $5.50 Million | $7.00 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $20.69 Million | $13.45 Million | $35.18 Million | $33.32 Million | $38.62 Million |
| Total Current Liabilities | $20.69 Million | $11.82 Million | $31.89 Million | $12.64 Million | $17.01 Million |
| Long-term Debt | — | — | — | $15.98 Million | $15.64 Million |
| Net Debt | $-26.86 Million | $-13.96 Million | $7.16 Million | $8.09 Million | $1.58 Million |
| Total Stockholder Equity | $147.50 Million | $142.43 Million | $-6.91 Million | $32.99 Million | $69.11 Million |
| Retained Earnings | $-555.43 Million | $-476.89 Million | $-436.68 Million | $-392.08 Million | $-349.73 Million |
Corbus Pharmaceuticals Holding Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Corbus Pharmaceuticals Holding generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-64.49 Million | $-41.79 Million | $-36.10 Billion | $-37.54 Million | $-48.18 Million |
| Capital Expenditures | $7.00K | $0.00 | $3.00 | $13.45K | $54.17K |
| Free Cash Flow | $-64.50 Million | $-41.79 Million | $-36.10 Billion | $-37.56 Million | $-48.24 Million |
| Investing Cash Flow | $-1.64 Million | $-121.31 Million | $35.64 Billion | $30.07 Million | $-73.42 Million |
| Financing Cash Flow | $77.43 Million | $166.58 Million | $-2.82 Billion | $-533.62K | $60.82 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $6.29 Million | $6.14 Million | $3.47 Billion | $5.72 Million | $9.48 Million |
| Depreciation | $-1.13 Million | $-2.74 Million | $640.60 Million | $1.49 Million | $1.64 Million |
| Change in Cash | $11.29 Million | $3.47 Million | $-3.28 Billion | $-8.00 Million | $-60.78 Million |
Corbus Pharmaceuticals Holding Earnings History — EPS Actual vs. Analyst Estimates
Track Corbus Pharmaceuticals Holding's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 06, 2026 | -1.81 | -1.30 | -39.23% |
| May 12, 2026 | -1.23 | -1.22 | -0.82% |
| Mar 09, 2026 | -1.25 | -1.58 | +20.69% |
| Nov 12, 2025 | -1.90 | -1.71 | -11.11% |
| Aug 05, 2025 | -1.44 | -1.33 | -8.27% |
| May 06, 2025 | -1.39 | -1.07 | -29.91% |
| Mar 10, 2025 | -0.78 | -1.26 | +38.04% |
| Nov 07, 2024 | -1.15 | -0.95 | -21.05% |